Horizon制药公共 HZNP 深 沪
等待开盘 05-18 09:30:00 美东时间
116.30
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 116.30
- 总市值 2663.27万
- 52周最高 116.38
- 市盈率 静 52.46
- 换手率 0.00%
- 52周最低 60.03
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 120.535
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.965
- 每 手 1
- 风险率 0.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Fennec Pharmaceuticals (NASDAQ:FENC) released first-quarter financial results a...
05-14 21:32
AnaptysBio appoints Christopher Murphy as CFO
AnaptysBio (ANAB) on Monday announced the appointment of Christopher Murphy as Chief Financial Officer. Murphy, previously, served as CFO and CBO of Third Harmonic Bio. Before Third Harmonic, he serve...
05-11 21:25
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
AnaptysBio appoints Christopher Murphy as CFO and Owen Hughes to its Board, enhancing expertise in finance, business development, and royalty management. Murphy brings extensive experience in corporate strategy and investment banking, while Hughes has over two decades of leadership in royalty management and corporate development. AnaptysBio focuses on managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to pr...
05-11 13:15
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma appoints Shao-Lee Lin, M.D., Ph.D., as CEO and President. Dr. Lin brings over 25 years of biopharmaceutical leadership experience, including successful IPOs and regulatory approvals. She will lead the advancement of CUE-401, a novel therapeutic for autoimmune diseases, and expand the clinical pipeline. Cue Biopharma focuses on developing innovative therapies targeting T cells to address autoimmune and inflammatory conditions.
04-30 20:05
FACTBOX-Major deals involving U.S. drugmakers and biotechs over the past decade
July 9 (Reuters) - Merck MRK.N is acquiring UK-based Verona Pharma VRNA.O for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda....
2025-07-10 01:28
UPDATE 2-Amgen posts profit, says tax policy more effective than tariffs
Adjusted EPS $4.90 vs LSEG estimate of $4.30 Revenue of $8.1 billion in line with Wall Street estimates 2025 outlook reaffirmed Recasts to include tariff comment; adds company comment paragraph 3, bac...
2025-05-02 05:01
Amgen quarterly profit tops Wall Street view, sales up 11%
Adjusted EPS $4.90 vs LSEG estimate of $4.30 Revenue of $8.1 billion in line with Wall Street estimates FDA lifts clinical hold on AMG 513 weight-loss drug trial By Deena Beasley May 1 (Reuters) - Amg...
2025-05-02 04:03
RBC Capital：上调安进评级至“跑赢大盘” 目标价上调至300美元
RBC Capital将制药商安进的评级从“与行业一致”上调至“跑赢大盘”，目标价从256美元上调至300美元。该行称，由于公司的基本业务表现趋于稳定、收购H...
2023-12-15 17:43
美国众议院监督委员会主席调查FTC在安进-Horizon合并中的行为
【美国众议院监督委员会主席调查FTC在安进-Horizon合并中的行为】财联社11月21日电，美国众议院监督委员会主席James Comer启动一项调查，剑指联...
2023-11-21 04:40
快讯 | 美国众议院监督委员会主席James Comer启动一项调查，剑指联邦贸易委员会（FTC）在“安进收购Horizon Therapeutics”之前对商业机密信息的保护工作。
美国众议院监督委员会主席James Comer启动一项调查，剑指联邦贸易委员会（FTC）在“安进收购Horizon Therapeutics”之前对商业机密信息...
2023-11-21 04:30
